首页 > 最新文献

Health Economics Review最新文献

英文 中文
Measuring utility values of eye conditions among children in India using the EQ-5D-Y instrument. 使用 EQ-5D-Y 工具测量印度儿童眼疾的效用值。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-09-07 DOI: 10.1186/s13561-024-00552-0
Sunny Mannava, Rishi Raj Borah, B R Shamanna

Background: Vision impairment and blindness are significant global public health challenges, particularly in low- and middle-income countries, where access to eye care services remains limited. India has significantly reduced the prevalence of Blindness and Vision Impairment (VI) over the last two decades. This was achieved with the help of greater investments towards blindness control programs. The use of utility values helps in conducting economic evaluations of various eye health programs and empirically justify investing in these programs. This study aimed to estimate utility values for various childhood eye conditions in central India using the EuroQol-Five-Dimension-Youth (EQ-5D-Y) instrument.

Methods: This is a before and after study with data collected at two time points for few participants and at only one time point for others. This study was undertaken at Shri Sadguru Netra Chikitsalaya (SNC) and included children representing central and north India. Participants were randomly sampled in the hospital. After comprehensive eye examination, participants completed the EuroQol-Five-Dimension-Youth (EQ-5D-Y) questionnaire along with EuroQol Visual Analogue Scale (EQ VAS) measurement to elicit their health state for their condition which was repeated after six months post-intervention to measure the change in utility value. We have used Indonesian value set to analyze the preference scores of each dimension of EQ-5D-Y.

Results: Utility values of 16 eye conditions were estimated at baseline and seven conditions were followed up for post-intervention utility value estimation. There is a statistically significant improvement in the utility values post-intervention amongst six conditions. Blindness and Pediatric cataract had the greatest change (0.23 and 0.2 respectively) in utility value whereas mild Vision Impairment (VI) showed the least change (0.02) in the utility value post-intervention. Blindness had the lowest baseline (0.62) and post-intervention (0.85) utility value.

Conclusion: The utility values estimated in this study showed that generic measures such as EQ-5D-Y may be used to elicit health states for various eye conditions amongst children. These estimates are helpful in undertaking cost-utility analyses of eye health programs and interventions aimed at these eye conditions.

背景:视力损伤和失明是全球公共卫生面临的重大挑战,尤其是在中低收入国家,这些国家的眼科保健服务仍然有限。在过去的二十年里,印度大幅降低了盲症和视力损伤(VI)的发病率。这得益于对防盲项目的更多投资。使用效用值有助于对各种眼健康项目进行经济评估,并从经验上证明投资这些项目的合理性。本研究旨在使用欧洲五维儿童质量标准(EQ-5D-Y)估算印度中部地区各种儿童眼病的效用值:这是一项前后对比研究,少数参与者在两个时间点收集数据,其他参与者只在一个时间点收集数据。这项研究在 Shri Sadguru Netra Chikitsalaya(SNC)进行,包括印度中部和北部的儿童。参与者在医院内随机抽样。在进行了全面的眼部检查后,参与者填写了 EuroQol-Five-Dimension-Youth (EQ-5D-Y) 问卷和 EuroQol Visual Analogue Scale (EQ VAS) 测量表,以了解他们的健康状况,并在干预后六个月重复测量,以衡量效用值的变化。我们使用印尼价值集来分析 EQ-5D-Y 各维度的偏好得分:结果:对 16 种眼部状况的效用值进行了基线估算,并对 7 种状况进行了干预后效用值估算。干预后,有六种情况的效用值在统计学上有明显改善。失明和小儿白内障的效用值变化最大(分别为 0.23 和 0.2),而轻度视力障碍(VI)在干预后的效用值变化最小(0.02)。失明的效用值基线最低(0.62),干预后最低(0.85):本研究估算的效用值表明,EQ-5D-Y 等通用测量方法可用于了解儿童各种眼部疾病的健康状况。这些估计值有助于对针对这些眼疾的眼健康计划和干预措施进行成本效用分析。
{"title":"Measuring utility values of eye conditions among children in India using the EQ-5D-Y instrument.","authors":"Sunny Mannava, Rishi Raj Borah, B R Shamanna","doi":"10.1186/s13561-024-00552-0","DOIUrl":"10.1186/s13561-024-00552-0","url":null,"abstract":"<p><strong>Background: </strong>Vision impairment and blindness are significant global public health challenges, particularly in low- and middle-income countries, where access to eye care services remains limited. India has significantly reduced the prevalence of Blindness and Vision Impairment (VI) over the last two decades. This was achieved with the help of greater investments towards blindness control programs. The use of utility values helps in conducting economic evaluations of various eye health programs and empirically justify investing in these programs. This study aimed to estimate utility values for various childhood eye conditions in central India using the EuroQol-Five-Dimension-Youth (EQ-5D-Y) instrument.</p><p><strong>Methods: </strong>This is a before and after study with data collected at two time points for few participants and at only one time point for others. This study was undertaken at Shri Sadguru Netra Chikitsalaya (SNC) and included children representing central and north India. Participants were randomly sampled in the hospital. After comprehensive eye examination, participants completed the EuroQol-Five-Dimension-Youth (EQ-5D-Y) questionnaire along with EuroQol Visual Analogue Scale (EQ VAS) measurement to elicit their health state for their condition which was repeated after six months post-intervention to measure the change in utility value. We have used Indonesian value set to analyze the preference scores of each dimension of EQ-5D-Y.</p><p><strong>Results: </strong>Utility values of 16 eye conditions were estimated at baseline and seven conditions were followed up for post-intervention utility value estimation. There is a statistically significant improvement in the utility values post-intervention amongst six conditions. Blindness and Pediatric cataract had the greatest change (0.23 and 0.2 respectively) in utility value whereas mild Vision Impairment (VI) showed the least change (0.02) in the utility value post-intervention. Blindness had the lowest baseline (0.62) and post-intervention (0.85) utility value.</p><p><strong>Conclusion: </strong>The utility values estimated in this study showed that generic measures such as EQ-5D-Y may be used to elicit health states for various eye conditions amongst children. These estimates are helpful in undertaking cost-utility analyses of eye health programs and interventions aimed at these eye conditions.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"72"},"PeriodicalIF":2.7,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of post-COVID-19 changes in outpatient chronic patients' healthcare-seeking behaviors on medical utilization and health outcomes. COVID-19 后门诊慢性病患者就医行为的变化对医疗利用率和健康结果的影响。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-09-05 DOI: 10.1186/s13561-024-00553-z
Wei-Lun Huang, Shu-Lang Liao, Hsueh-Ling Huang, Pei-Ju Tsai, Hsin-Hsun Huang, Chien-Yu Lu, Wei-Sho Ho

Introduction: This study comprehensively investigates the changes in healthcare utilization among chronic patients with regular outpatient visits to hospitals after the occurrence of Covid-19. The research examines whether patients altered their originally regular medical attendance frequencies due to the pandemic and explores potential negative impacts on the health conditions of those irregular attendees post-pandemic.

Methods: Data for this study were sourced from a database at a medical center in Taiwan. The subjects were chronic patients with regular hospital outpatient visits before the Covid-19 outbreak. The study tracked medical utilization patterns from 2017 to 2022 for different patient characteristics and outpatient behaviors, employing statistical methods such as Repeated Measures ANOVA and Generalized Estimating Equation to analyze changes in healthcare utilization and health status during the post-pandemic period.

Results: The results reveal that, compared to the regular group, chronic patients with irregular outpatient visits during the post-pandemic period exhibited a decrease of 5.85 annual outpatient visits, a reduction of NT$20,290.1 in annual medical expenses, and a significantly higher abnormality rate in average biochemical test results by 0.9%.

Conclusions: The findings contribute to understanding the impact of the Covid-19 pandemic on healthcare utilization and health conditions among outpatient chronic disease populations. In response to the new medical landscape in the post-pandemic era, proactive suggestions are made, including providing telemedicine outpatient services and referral-based medical care to meet the needs of the target population, ensuring a continuous and reassuring healthcare model for chronic patients, and mitigating the operational impacts of public health emergencies on hospitals.

简介本研究全面调查了Covid-19疫情发生后,定期到医院门诊就诊的慢性病患者在使用医疗服务方面的变化。研究探讨了患者是否因大流行而改变了其原本的固定就诊频率,并探讨了大流行后对这些不固定就诊者的健康状况可能产生的负面影响:本研究的数据来自台湾一家医疗中心的数据库。研究对象是在 Covid-19 爆发前定期到医院门诊就诊的慢性病患者。研究追踪了2017年至2022年不同患者特征和门诊行为的医疗利用模式,采用重复测量方差分析和广义估计方程等统计方法,分析疫情后医疗利用和健康状况的变化:结果显示,与正常组相比,大流行后不定期门诊的慢性病患者年门诊量减少5.85人次,年医疗费用减少20290.1元,平均生化检验结果异常率显著增加0.9%:这些研究结果有助于了解 Covid-19 大流行对门诊慢性病患者的医疗利用率和健康状况的影响。针对后大流行时代的医疗新格局,提出了积极的建议,包括提供远程医疗门诊服务和基于转诊的医疗服务,以满足目标人群的需求,确保为慢性病患者提供持续和放心的医疗保健模式,以及减轻突发公共卫生事件对医院运营的影响。
{"title":"Impact of post-COVID-19 changes in outpatient chronic patients' healthcare-seeking behaviors on medical utilization and health outcomes.","authors":"Wei-Lun Huang, Shu-Lang Liao, Hsueh-Ling Huang, Pei-Ju Tsai, Hsin-Hsun Huang, Chien-Yu Lu, Wei-Sho Ho","doi":"10.1186/s13561-024-00553-z","DOIUrl":"10.1186/s13561-024-00553-z","url":null,"abstract":"<p><strong>Introduction: </strong>This study comprehensively investigates the changes in healthcare utilization among chronic patients with regular outpatient visits to hospitals after the occurrence of Covid-19. The research examines whether patients altered their originally regular medical attendance frequencies due to the pandemic and explores potential negative impacts on the health conditions of those irregular attendees post-pandemic.</p><p><strong>Methods: </strong>Data for this study were sourced from a database at a medical center in Taiwan. The subjects were chronic patients with regular hospital outpatient visits before the Covid-19 outbreak. The study tracked medical utilization patterns from 2017 to 2022 for different patient characteristics and outpatient behaviors, employing statistical methods such as Repeated Measures ANOVA and Generalized Estimating Equation to analyze changes in healthcare utilization and health status during the post-pandemic period.</p><p><strong>Results: </strong>The results reveal that, compared to the regular group, chronic patients with irregular outpatient visits during the post-pandemic period exhibited a decrease of 5.85 annual outpatient visits, a reduction of NT$20,290.1 in annual medical expenses, and a significantly higher abnormality rate in average biochemical test results by 0.9%.</p><p><strong>Conclusions: </strong>The findings contribute to understanding the impact of the Covid-19 pandemic on healthcare utilization and health conditions among outpatient chronic disease populations. In response to the new medical landscape in the post-pandemic era, proactive suggestions are made, including providing telemedicine outpatient services and referral-based medical care to meet the needs of the target population, ensuring a continuous and reassuring healthcare model for chronic patients, and mitigating the operational impacts of public health emergencies on hospitals.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"71"},"PeriodicalIF":2.7,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021-2030): a societal perspective. 西班牙视力丧失和不可逆转的法定失明经济负担评估(2021-2030 年):社会视角。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-09-03 DOI: 10.1186/s13561-024-00546-y
Luis Pablo, Gonzaga Garay-Aramburu, Alfredo García Layana, Anxo Fernandez, Inmaculada Vázquez, Xenia Acebes, Jacinto Zulueta, Delfina Balonga, Laura Salinas-Ortega, Álvaro Muñoz, Araceli Casado Gómez, Miguel Ángel Casado, Julia Salvador, Inmaculada Bañón-Rodriguez, José María Ruíz-Moreno

Objective: To estimate the economic impact for the society, generated as a consequence of the onset of loss of vision and irreversible legal blindness, for the main ophthalmologic diseases in Spain: glaucoma, diabetic retinopathy (DR), diabetic macular edema (DME), age-related macular degeneration (AMD) and high myopia (HM).

Methods: A cost analysis model was developed to estimate the economic burden of glaucoma, DR, DME, AMD and HM over a 10-year time horizon (2021-2030), from a societal perspective in Spain. The epidemiological and economic parameters used in the model were obtained through a literature review. Prevalence, incidence, and progression stages were used to establish the epidemiological flows. Annual costs per patient from publications were included and classified into direct healthcare, direct non-healthcare and indirect costs. Costs from other countries were converted based on purchasing-power-parity (€EUR, PPP). Epidemiological parameters about population and cost results were validated by a panel of experts. All costs were adjusted to euros, 2021 (€, 2021), and using the Consumer Price Index (CPI) of the last 10 years, extrapolated to 2030 euros (€, 2030).

Results: It was estimated that the total population of patients with the main diseases pathologies (glaucoma, DR, DME, AMD and HM) will increase to 7.99 million patients by 2030, representing an increase of 103%. The total cost by 2030 of all pathologies would amount to 99.8 billion euros. Direct non-healthcare costs account for the largest item (44%), followed by loss of productivity costs (38%), and direct healthcare costs (18%). The pathologies with the highest cumulative costs will be glaucoma (€33.6 billion) and DME (€19.8 billion).The greatest increment costs compared to 2021 will likely be generated by pathologies related to diabetes mellitus, such as DR (703%) and DME (317%).

Conclusions: Knowing the costs associated with the pathologies that generate loss of vision and irreversible legal blindness is essential to understand the socioeconomic impact associated with these pathologies. Furthermore, the high cost of treating these diseases makes necessary to coordinate efforts between administrations, together with the support of patient associations, to meet their needs.

目的估算西班牙主要眼科疾病:青光眼、糖尿病视网膜病变(DR)、糖尿病黄斑水肿(DME)、年龄相关性黄斑变性(AMD)和高度近视(HM)对社会造成的经济影响:方法:建立了一个成本分析模型,从西班牙社会的角度估算青光眼、DR、DME、AMD 和 HM 在 10 年时间跨度内(2021-2030 年)的经济负担。模型中使用的流行病学和经济学参数是通过文献综述获得的。流行率、发病率和进展阶段用于建立流行病学流程。每名患者的年度成本包括出版物中的成本,并分为直接医疗成本、直接非医疗成本和间接成本。其他国家的成本根据购买力平价(欧元,购买力平价)进行换算。有关人口和成本结果的流行病学参数由专家小组进行验证。所有费用均调整为 2021 年欧元(€,2021 年),并根据过去 10 年的消费价格指数(CPI)推算至 2030 年欧元(€,2030 年):据估计,到 2030 年,主要疾病(青光眼、DR、DME、AMD 和 HM)患者总数将增至 799 万人,增幅达 103%。到 2030 年,所有病症的总费用将达到 998 亿欧元。直接非医疗成本占最大部分(44%),其次是生产力损失成本(38%)和直接医疗成本(18%)。累计成本最高的病症将是青光眼(336 亿欧元)和眼底病(198 亿欧元)。与 2021 年相比,与糖尿病相关的病症可能会产生最大的成本增长,如 DR(703%)和眼底病(317%):了解造成视力丧失和不可逆转的法定失明的病症的相关成本,对于了解这些病症的社会经济影响至关重要。此外,这些疾病的治疗费用高昂,因此有必要在患者协会的支持下,协调各行政部门的工作,以满足他们的需求。
{"title":"Assessing the economic burden of vision loss and irreversible legal blindness in Spain (2021-2030): a societal perspective.","authors":"Luis Pablo, Gonzaga Garay-Aramburu, Alfredo García Layana, Anxo Fernandez, Inmaculada Vázquez, Xenia Acebes, Jacinto Zulueta, Delfina Balonga, Laura Salinas-Ortega, Álvaro Muñoz, Araceli Casado Gómez, Miguel Ángel Casado, Julia Salvador, Inmaculada Bañón-Rodriguez, José María Ruíz-Moreno","doi":"10.1186/s13561-024-00546-y","DOIUrl":"10.1186/s13561-024-00546-y","url":null,"abstract":"<p><strong>Objective: </strong>To estimate the economic impact for the society, generated as a consequence of the onset of loss of vision and irreversible legal blindness, for the main ophthalmologic diseases in Spain: glaucoma, diabetic retinopathy (DR), diabetic macular edema (DME), age-related macular degeneration (AMD) and high myopia (HM).</p><p><strong>Methods: </strong>A cost analysis model was developed to estimate the economic burden of glaucoma, DR, DME, AMD and HM over a 10-year time horizon (2021-2030), from a societal perspective in Spain. The epidemiological and economic parameters used in the model were obtained through a literature review. Prevalence, incidence, and progression stages were used to establish the epidemiological flows. Annual costs per patient from publications were included and classified into direct healthcare, direct non-healthcare and indirect costs. Costs from other countries were converted based on purchasing-power-parity (€EUR, PPP). Epidemiological parameters about population and cost results were validated by a panel of experts. All costs were adjusted to euros, 2021 (€, 2021), and using the Consumer Price Index (CPI) of the last 10 years, extrapolated to 2030 euros (€, 2030).</p><p><strong>Results: </strong>It was estimated that the total population of patients with the main diseases pathologies (glaucoma, DR, DME, AMD and HM) will increase to 7.99 million patients by 2030, representing an increase of 103%. The total cost by 2030 of all pathologies would amount to 99.8 billion euros. Direct non-healthcare costs account for the largest item (44%), followed by loss of productivity costs (38%), and direct healthcare costs (18%). The pathologies with the highest cumulative costs will be glaucoma (€33.6 billion) and DME (€19.8 billion).The greatest increment costs compared to 2021 will likely be generated by pathologies related to diabetes mellitus, such as DR (703%) and DME (317%).</p><p><strong>Conclusions: </strong>Knowing the costs associated with the pathologies that generate loss of vision and irreversible legal blindness is essential to understand the socioeconomic impact associated with these pathologies. Furthermore, the high cost of treating these diseases makes necessary to coordinate efforts between administrations, together with the support of patient associations, to meet their needs.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"70"},"PeriodicalIF":2.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney transplant cases in US: study of determinants of variance in hospital charges and inpatient care. 美国肾移植病例:医院收费和住院护理差异的决定因素研究。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-09-02 DOI: 10.1186/s13561-024-00525-3
Aigbe Akhigbe, Ravi Chinta

We investigate the factors that influence the variance in hospital charges and inpatient care for kidney transplant cases in the US. Using the AHRQ's (Agency for Healthcare Research and Quality) HCUP's (Hospital Cost and Utilization Project) NIS (National Inpatient Sample) database, we find that variance in hospital charges and inpatient care is driven by patient demographics and hospital variables. We find that variance in hospital charges and inpatient care is determined by patient-specific factors including age, gender, race, and income, and hospital factors such as size, type, and location. Our results provide a deeper understanding of the non-clinical factors that impact hospital charges and inpatient care for kidney transplant patients.

我们调查了影响美国肾移植病例住院费用和住院护理差异的因素。利用 AHRQ(医疗保健研究与质量机构)的 HCUP(医院成本与利用项目)NIS(全国住院病人抽样)数据库,我们发现医院收费和住院护理的差异是由病人人口统计学和医院变量驱动的。我们发现,医院收费和住院护理的差异是由患者的特定因素(包括年龄、性别、种族和收入)以及医院的因素(如规模、类型和地点)决定的。我们的研究结果加深了人们对影响肾移植患者住院费用和住院护理的非临床因素的理解。
{"title":"Kidney transplant cases in US: study of determinants of variance in hospital charges and inpatient care.","authors":"Aigbe Akhigbe, Ravi Chinta","doi":"10.1186/s13561-024-00525-3","DOIUrl":"10.1186/s13561-024-00525-3","url":null,"abstract":"<p><p>We investigate the factors that influence the variance in hospital charges and inpatient care for kidney transplant cases in the US. Using the AHRQ's (Agency for Healthcare Research and Quality) HCUP's (Hospital Cost and Utilization Project) NIS (National Inpatient Sample) database, we find that variance in hospital charges and inpatient care is driven by patient demographics and hospital variables. We find that variance in hospital charges and inpatient care is determined by patient-specific factors including age, gender, race, and income, and hospital factors such as size, type, and location. Our results provide a deeper understanding of the non-clinical factors that impact hospital charges and inpatient care for kidney transplant patients.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"69"},"PeriodicalIF":2.7,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11370305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of food price inflation on stunting in under five aged children in Bangladesh. 食品价格上涨对孟加拉国五岁以下儿童发育迟缓的影响。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-29 DOI: 10.1186/s13561-024-00549-9
Sheikh Sifat Sadikeen, Nazmul Haque, Md Miraj Hossain, Md Jamal Uddin

Background: Currently, food price inflation is a widespread issue in Bangladesh as well as the rest of the world. Malnutrition is a common issue among children that can have long-lasting effects on their development and overall health. There have been lots of studies conducted to identify the factors responsible for child malnutrition, but inflation is rarely considered a factor in child malnutrition. We aimed to determine the relationship between food price inflation and stunting (Height-for-Age Z-score (HAZ)) in children under five years of age in Bangladesh.

Method: The study utilized food price data from the World Food Programme database and malnutrition (stunting) information from the 2014 and 2017-18 Bangladesh Demographic Health Surveys (BDHS). This includes the total study period from 2009 to 2018. Food prices were linked to the BDHS dataset using each child's birth month. For each child, the average food prices from 9 months prior to 5 months post-birth, including their birth month, were recorded to calculate month-to-month inflation. This inflation was computed for rice (coarse), oil, wheat flour, and lentils by comparing the price sum of each item from one month to the previous month and dividing by the total price of the preceding month. A generalized linear regression model was used to assess the relationship between food price inflation and stunting, with stunting as the dependent variable. Other explanatory variables included wealth index, sex of the child, height, weight, mother's education, respondent's current pregnancy, and breastfeeding status.

Results: Our study has revealed that food price inflation has a significant negative effect on stunting, with a coefficient of -0.127 (p < 0.001). Furthermore, we have identified several other factors that have also significantly negative associations with stunting, including the wealth index (p < 0.001), mother's education level (p < 0.001), mother's pregnancy status (p < 0.001), breastfeeding (p < 0.001), child's age (p < 0.001). child's weight (p < 0.001) has significantly positive effect on stunting. However, we did not find any significant differences in stunting between boys and girls.

Conclusion: In conclusion, the findings of this study underscore the significant negative impact of food price inflation on child stunting, emphasizing the need to acknowledge this factor alongside others. These results highlight the critical role of addressing food price inflation as a key determinant of stunting, in conjunction with various other contributing factors, in efforts to combat childhood malnutrition.

背景:目前,食品价格上涨是孟加拉国和世界其他国家普遍存在的问题。营养不良是儿童中常见的问题,会对他们的发育和整体健康造成长期影响。有很多研究都是为了确定造成儿童营养不良的因素,但通货膨胀很少被认为是造成儿童营养不良的一个因素。我们旨在确定食品价格上涨与孟加拉国五岁以下儿童发育迟缓(年龄身高 Z 值(HAZ))之间的关系:研究利用了世界粮食计划署数据库中的食品价格数据和2014年和2017-18年孟加拉国人口健康调查(BDHS)中的营养不良(发育迟缓)信息。这包括 2009 年至 2018 年的整个研究期间。食品价格通过每个儿童的出生月份与 BDHS 数据集进行了链接。记录每个儿童出生前 9 个月至出生后 5 个月的平均食品价格(包括其出生月份),以计算逐月通货膨胀率。计算大米(粗米)、油、小麦粉和小扁豆的通胀率的方法是,比较每种食品从一个月到前一个月的价格总和,然后除以前一个月的总价格。采用广义线性回归模型评估食品价格上涨与发育迟缓之间的关系,以发育迟缓为因变量。其他解释变量包括财富指数、儿童性别、身高、体重、母亲受教育程度、受访者目前是否怀孕以及母乳喂养状况:我们的研究表明,食品价格上涨对发育迟缓有显著的负面影响,系数为-0.127(p):总之,本研究的结果强调了食品价格上涨对儿童发育迟缓的重大负面影响,并强调有必要将这一因素与其他因素一并考虑。这些结果突出表明,在努力消除儿童营养不良现象的过程中,解决食品价格上涨问题作为发育迟缓的一个关键决定因素,与其他各种因素一起发挥着至关重要的作用。
{"title":"Impact of food price inflation on stunting in under five aged children in Bangladesh.","authors":"Sheikh Sifat Sadikeen, Nazmul Haque, Md Miraj Hossain, Md Jamal Uddin","doi":"10.1186/s13561-024-00549-9","DOIUrl":"10.1186/s13561-024-00549-9","url":null,"abstract":"<p><strong>Background: </strong>Currently, food price inflation is a widespread issue in Bangladesh as well as the rest of the world. Malnutrition is a common issue among children that can have long-lasting effects on their development and overall health. There have been lots of studies conducted to identify the factors responsible for child malnutrition, but inflation is rarely considered a factor in child malnutrition. We aimed to determine the relationship between food price inflation and stunting (Height-for-Age Z-score (HAZ)) in children under five years of age in Bangladesh.</p><p><strong>Method: </strong>The study utilized food price data from the World Food Programme database and malnutrition (stunting) information from the 2014 and 2017-18 Bangladesh Demographic Health Surveys (BDHS). This includes the total study period from 2009 to 2018. Food prices were linked to the BDHS dataset using each child's birth month. For each child, the average food prices from 9 months prior to 5 months post-birth, including their birth month, were recorded to calculate month-to-month inflation. This inflation was computed for rice (coarse), oil, wheat flour, and lentils by comparing the price sum of each item from one month to the previous month and dividing by the total price of the preceding month. A generalized linear regression model was used to assess the relationship between food price inflation and stunting, with stunting as the dependent variable. Other explanatory variables included wealth index, sex of the child, height, weight, mother's education, respondent's current pregnancy, and breastfeeding status.</p><p><strong>Results: </strong>Our study has revealed that food price inflation has a significant negative effect on stunting, with a coefficient of -0.127 (p < 0.001). Furthermore, we have identified several other factors that have also significantly negative associations with stunting, including the wealth index (p < 0.001), mother's education level (p < 0.001), mother's pregnancy status (p < 0.001), breastfeeding (p < 0.001), child's age (p < 0.001). child's weight (p < 0.001) has significantly positive effect on stunting. However, we did not find any significant differences in stunting between boys and girls.</p><p><strong>Conclusion: </strong>In conclusion, the findings of this study underscore the significant negative impact of food price inflation on child stunting, emphasizing the need to acknowledge this factor alongside others. These results highlight the critical role of addressing food price inflation as a key determinant of stunting, in conjunction with various other contributing factors, in efforts to combat childhood malnutrition.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"68"},"PeriodicalIF":2.7,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142113347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data. 利用 LIBERTY ASTHMA QUEST 韩国数据,对未受控的重症哮喘患者进行杜必鲁单抗成本效益分析。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-26 DOI: 10.1186/s13561-024-00532-4
Sung-Hee Oh, Chin Kook Rhee, Eun Jin Bae, Hyemin Ku

Background: A sub-analysis of the Korean population in the LIBERTY ASTHMA QUEST trial (NCT02414854) revealed that dupilumab effectively treated severe uncontrolled asthma. This study aimed to assess the cost-effectiveness of add-on therapy with dupilumab to background therapy in patients ≥ 12 years of age with uncontrolled severe asthma compared to that of background therapy in South Korea.

Methods: The cost-effectiveness analysis was conducted using a Markov model over a lifetime from the Korean healthcare system perspective. Clinical efficacy and utility weights were obtained from post-hoc analyses of the Korean population in the QUEST trial. Data on the costs and treatment setting of exacerbation in a real-world setting were retrospectively collected using the administrative medical database from a single tertiary hospital.

Results: The base-case results indicated that add-on dupilumab therapy increases costs ($112,924 for add-on dupilumab versus $29,545 for background therapy alone). However, add-on dupilumab increased quality-adjusted life years (QALYs, 8.03 versus 3.93, respectively), with fewer events of severe exacerbations per patient compared to using the background therapy alone (17.920 versus 19.911, respectively). The incremental cost-effectiveness ratio was $20,325 per QALY. Various sensitivity analyses supported the robustness of the base-case results. Probabilistic sensitivity analysis showed that the probability of add-on dupilumab being cost-effective was 87% at a threshold willingness-to-pay of $26,718 (KRW 35 million) per QALY gained.

Conclusions: Dupilumab is cost-effective for adolescents and adults with uncontrolled severe asthma in South Korea. Our study provides evidence to support clinicians and policymakers in making informed decisions for severe asthma management.

研究背景LIBERTY ASTHMA QUEST试验(NCT02414854)对韩国人群进行的子分析表明,dupilumab能有效治疗未受控制的重症哮喘。本研究旨在评估在韩国,与背景疗法相比,对年龄≥12岁的未受控重症哮喘患者在背景疗法基础上加用杜比单抗的成本效益:成本效益分析采用马尔可夫模型,从韩国医疗保健系统的角度对患者的一生进行分析。临床疗效和效用权重来自 QUEST 试验中韩国人群的事后分析。通过一家三级医院的行政医疗数据库回顾性收集了现实世界中病情加重的成本和治疗环境数据:基础研究结果表明,加用杜比单抗会增加成本(加用杜比单抗的成本为 112,924 美元,而单独使用背景疗法的成本为 29,545 美元)。然而,与单独使用背景疗法相比,附加双珠单抗疗法增加了质量调整生命年(QALYs,分别为 8.03 对 3.93),每位患者的严重病情加重事件也减少了(分别为 17.920 对 19.911)。每 QALY 的增量成本效益比为 20,325 美元。各种敏感性分析证实了基础病例结果的稳健性。概率敏感性分析表明,在每QALY收益26,718美元(3500万韩元)的支付意愿阈值下,附加杜比单抗具有成本效益的概率为87%:结论:在韩国,杜匹单抗对患有不受控制的重症哮喘的青少年和成人具有成本效益。我们的研究为临床医生和政策制定者在重症哮喘管理方面做出明智决策提供了证据支持。
{"title":"Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data.","authors":"Sung-Hee Oh, Chin Kook Rhee, Eun Jin Bae, Hyemin Ku","doi":"10.1186/s13561-024-00532-4","DOIUrl":"10.1186/s13561-024-00532-4","url":null,"abstract":"<p><strong>Background: </strong>A sub-analysis of the Korean population in the LIBERTY ASTHMA QUEST trial (NCT02414854) revealed that dupilumab effectively treated severe uncontrolled asthma. This study aimed to assess the cost-effectiveness of add-on therapy with dupilumab to background therapy in patients ≥ 12 years of age with uncontrolled severe asthma compared to that of background therapy in South Korea.</p><p><strong>Methods: </strong>The cost-effectiveness analysis was conducted using a Markov model over a lifetime from the Korean healthcare system perspective. Clinical efficacy and utility weights were obtained from post-hoc analyses of the Korean population in the QUEST trial. Data on the costs and treatment setting of exacerbation in a real-world setting were retrospectively collected using the administrative medical database from a single tertiary hospital.</p><p><strong>Results: </strong>The base-case results indicated that add-on dupilumab therapy increases costs ($112,924 for add-on dupilumab versus $29,545 for background therapy alone). However, add-on dupilumab increased quality-adjusted life years (QALYs, 8.03 versus 3.93, respectively), with fewer events of severe exacerbations per patient compared to using the background therapy alone (17.920 versus 19.911, respectively). The incremental cost-effectiveness ratio was $20,325 per QALY. Various sensitivity analyses supported the robustness of the base-case results. Probabilistic sensitivity analysis showed that the probability of add-on dupilumab being cost-effective was 87% at a threshold willingness-to-pay of $26,718 (KRW 35 million) per QALY gained.</p><p><strong>Conclusions: </strong>Dupilumab is cost-effective for adolescents and adults with uncontrolled severe asthma in South Korea. Our study provides evidence to support clinicians and policymakers in making informed decisions for severe asthma management.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"67"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estimating the cost for obstetric fistula repair in hospitals of Mozambique: a low-income country. 莫桑比克(低收入国家)医院产科瘘管修补费用估算。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-26 DOI: 10.1186/s13561-024-00542-2
Nelmo Jordão Manjate, Janet Dulá Martins, Regina Amado, Armindo Nhanombe, Neide Canana, Laurentino Cumbi, Germano Pires, Elídio Muamine, Maria Isabel Cambe, Ausenda Domingos, Sérgio Chicumbe

Background: Obstetric fistula is incident and prevalent in low-income countries. Globally, about 100,000 women develop fistula annually. In Mozambique, more than 2,000 fistulas are reported annually. A national strategy to combat obstetric fistula has been implemented in Mozambique from 2012-2020. This strategy is under review, making it opportune to generate evidence that reflects the course of the strategy implemented to subsidize/optimize the definition of priorities of the new strategy to achieve universal health coverage. In Mozambique, information on the costs incurred to treat fistula is scarce. This study aims to estimate the mean unit cost of repair/treatment of simple and complex obstetric fistula in Mozambique.

Methods: We carried out a retrospective evaluation, from the provider's perspective, using the Ingredient and Stepdown approaches. The mean unit cost was obtained by the sum of individual and shared ingredients to treat fistula. Cost dimensions included Direct Medical Costs (personnel, drugs, and supplies), Overhead and Capital Costs (administration and capital assets' costs, respectively). The average exchange rate was USD 1 = MZN 61.47. Data were collected in secondary, tertiary, and quaternary hospitals of Zambézia and Nampula provinces in 2021. Costs borne by patients and their families and loss of productivity were not included.

Results: The mean cost for Simple Obstetric Fistula repair was MZN 14,937.21 (USD 243) and Complex Obstetric Fistula was MZN 21,145.68 (USD 344) per person operated. Regardless of the type of fistula, the repair cost was MZN 18,072.18 (USD 294).

Conclusion: Without neglecting that prevention is better than plasty, the results show feasible levels of fistula repair costs for mobilization of funds. For the estimated 2,000 fistulas reported annually, the government needs an average MZN 36,144,360 (USD 588,000).

背景:产科瘘管病是低收入国家的常见病和多发病。全球每年约有 10 万名妇女患上瘘管病。在莫桑比克,每年报告的瘘管病例超过 2 000 例。莫桑比克实施了 2012-2020 年防治产科瘘管病国家战略。目前正在对该战略进行审查,因此有必要提供证据,以反映该战略的实施过程,从而为实现全民医保的新战略确定优先事项提供支持/优化。在莫桑比克,有关瘘管病治疗费用的信息很少。本研究旨在估算莫桑比克修复/治疗简单和复杂产科瘘管病的平均单位成本:方法:我们从医疗服务提供者的角度出发,采用 "成分法 "和 "分步法 "进行了回顾性评估。平均单位成本由治疗瘘管的单项成本和分摊成本之和得出。成本维度包括直接医疗成本(人员、药品和用品)、间接成本和资本成本(分别为管理成本和资本资产成本)。平均汇率为 1 美元 = 61.47 姆兹罗提。数据于 2021 年在赞比西亚省和楠普拉省的二级、三级和四级医院收集。患者及其家属承担的费用和生产力损失未包括在内:简单产科瘘管修补术的平均费用为每人14,937.21马币(243美元),复杂产科瘘管修补术的平均费用为每人21,145.68马币(344美元)。无论瘘管类型如何,修复费用均为 18,072.18 马扎尼(294 美元):结论:在不忽视预防胜于治疗的前提下,研究结果表明,瘘管修补费用在筹集资金方面是可行的。对于每年报告的约 2 000 例瘘管病,政府平均需要 36 144 360 姆扎伊尔(588 000 美元)。
{"title":"Estimating the cost for obstetric fistula repair in hospitals of Mozambique: a low-income country.","authors":"Nelmo Jordão Manjate, Janet Dulá Martins, Regina Amado, Armindo Nhanombe, Neide Canana, Laurentino Cumbi, Germano Pires, Elídio Muamine, Maria Isabel Cambe, Ausenda Domingos, Sérgio Chicumbe","doi":"10.1186/s13561-024-00542-2","DOIUrl":"10.1186/s13561-024-00542-2","url":null,"abstract":"<p><strong>Background: </strong>Obstetric fistula is incident and prevalent in low-income countries. Globally, about 100,000 women develop fistula annually. In Mozambique, more than 2,000 fistulas are reported annually. A national strategy to combat obstetric fistula has been implemented in Mozambique from 2012-2020. This strategy is under review, making it opportune to generate evidence that reflects the course of the strategy implemented to subsidize/optimize the definition of priorities of the new strategy to achieve universal health coverage. In Mozambique, information on the costs incurred to treat fistula is scarce. This study aims to estimate the mean unit cost of repair/treatment of simple and complex obstetric fistula in Mozambique.</p><p><strong>Methods: </strong>We carried out a retrospective evaluation, from the provider's perspective, using the Ingredient and Stepdown approaches. The mean unit cost was obtained by the sum of individual and shared ingredients to treat fistula. Cost dimensions included Direct Medical Costs (personnel, drugs, and supplies), Overhead and Capital Costs (administration and capital assets' costs, respectively). The average exchange rate was USD 1 = MZN 61.47. Data were collected in secondary, tertiary, and quaternary hospitals of Zambézia and Nampula provinces in 2021. Costs borne by patients and their families and loss of productivity were not included.</p><p><strong>Results: </strong>The mean cost for Simple Obstetric Fistula repair was MZN 14,937.21 (USD 243) and Complex Obstetric Fistula was MZN 21,145.68 (USD 344) per person operated. Regardless of the type of fistula, the repair cost was MZN 18,072.18 (USD 294).</p><p><strong>Conclusion: </strong>Without neglecting that prevention is better than plasty, the results show feasible levels of fistula repair costs for mobilization of funds. For the estimated 2,000 fistulas reported annually, the government needs an average MZN 36,144,360 (USD 588,000).</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"65"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Policies and cost analyses of voluntary assisted dying (VAD) laws - a mapping review & analysis. 自愿协助死亡(VAD)法律的政策和成本分析--绘图审查与分析。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-26 DOI: 10.1186/s13561-024-00547-x
Sami Isaac, Andrew J McLachlan, Betty Chaar

Objectives: To investigate the current literature on healthcare policies and cost analyses around international Voluntary Assisted Dying (VAD) laws. The study design is a mapping literature review following Preferred-Reporting-Items-for-Systematic-Reviews-and-Meta-Analyses (PRISMA) guidelines.

Methods: Original research articles published between January 1990 to March 2023, investigating the financial cost and healthcare budget effect of VAD laws internationally. Citations were screened for relevance and eligibility, and any non-full-text research that did not explore cost analysis was excluded. The following data sources were screened: MEDLINE, PubMed, EMBASE, CINAHL and any relevant international health authority annual reports were also reviewed.

Results: Of the 2790 screened articles, eight studies met the inclusion criteria and three were included in the mapping review. The reviewed studies included prospective studies, two Canadian and one US. Only one of the Canadian studies provided a cost analysis using data from current VAD laws. All three studies showed VAD laws would reduce healthcare spending, with the US approximating $627million in 1995. Canada approximating $17.1 to $77.1million in 2017 and $86.9 to $149.0million in 2021, overall, leading to an average percentage reduction in costs of approximately 87% compared to original costs of end-of-life care.

Conclusion: This review identifies a scarcity in cost-analysis literature and provides a summary of the latest international VAD laws, from which a potential cost reduction is apparent. The absence of retrospectively collated financial VAD data highlights a need for future research to inform policymakers of the economic factors affecting current policies with a need for annual fiscal reports and to optimise future legislative frameworks internationally.

目的调查有关国际自愿协助死亡(VAD)法律的医疗政策和成本分析的现有文献。研究设计为绘图文献综述,遵循 "系统综述与计量分析的首选报告项目"(Preferred-Reporting-Items-for-Systematic-Reviews-and-Meta-Analyses,PRISMA)指南:方法:1990 年 1 月至 2023 年 3 月间发表的原创研究文章,调查国际上 VAD 法律的财务成本和医疗预算影响。对引文的相关性和合格性进行筛选,排除任何未探讨成本分析的非全文研究。筛选了以下数据来源:MEDLINE、PubMed、EMBASE、CINAHL,并查阅了相关国际卫生机构的年度报告:在筛选出的 2790 篇文章中,有 8 项研究符合纳入标准,其中 3 项被纳入图谱审查。所审查的研究包括前瞻性研究,其中两项为加拿大研究,一项为美国研究。其中只有一项加拿大研究利用现行 VAD 法律的数据进行了成本分析。所有三项研究都表明,VAD 法律将减少医疗保健支出,1995 年美国约为 6.27 亿美元,加拿大约为 1.71 亿美元。加拿大在 2017 年约为 1,710 万至 7,710 万美元,在 2021 年约为 8,690 万至 1.490 亿美元,总体而言,与生命末期护理的原始成本相比,平均成本降低了约 87%:本综述发现了成本分析文献的稀缺性,并对最新的国际 VAD 法律进行了总结,从中可以看出潜在的成本降低。由于缺乏追溯整理的 VAD 财务数据,因此今后需要开展研究,以告知政策制定者影响现行政策的经济因素,同时需要编制年度财务报告,并优化国际上未来的立法框架。
{"title":"Policies and cost analyses of voluntary assisted dying (VAD) laws - a mapping review & analysis.","authors":"Sami Isaac, Andrew J McLachlan, Betty Chaar","doi":"10.1186/s13561-024-00547-x","DOIUrl":"10.1186/s13561-024-00547-x","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the current literature on healthcare policies and cost analyses around international Voluntary Assisted Dying (VAD) laws. The study design is a mapping literature review following Preferred-Reporting-Items-for-Systematic-Reviews-and-Meta-Analyses (PRISMA) guidelines.</p><p><strong>Methods: </strong>Original research articles published between January 1990 to March 2023, investigating the financial cost and healthcare budget effect of VAD laws internationally. Citations were screened for relevance and eligibility, and any non-full-text research that did not explore cost analysis was excluded. The following data sources were screened: MEDLINE, PubMed, EMBASE, CINAHL and any relevant international health authority annual reports were also reviewed.</p><p><strong>Results: </strong>Of the 2790 screened articles, eight studies met the inclusion criteria and three were included in the mapping review. The reviewed studies included prospective studies, two Canadian and one US. Only one of the Canadian studies provided a cost analysis using data from current VAD laws. All three studies showed VAD laws would reduce healthcare spending, with the US approximating $627million in 1995. Canada approximating $17.1 to $77.1million in 2017 and $86.9 to $149.0million in 2021, overall, leading to an average percentage reduction in costs of approximately 87% compared to original costs of end-of-life care.</p><p><strong>Conclusion: </strong>This review identifies a scarcity in cost-analysis literature and provides a summary of the latest international VAD laws, from which a potential cost reduction is apparent. The absence of retrospectively collated financial VAD data highlights a need for future research to inform policymakers of the economic factors affecting current policies with a need for annual fiscal reports and to optimise future legislative frameworks internationally.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"66"},"PeriodicalIF":2.7,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142056913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea. 哪个因素会减少药品支出:进入者数量还是价格差异?韩国仿制药市场的最新情况。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-14 DOI: 10.1186/s13561-024-00545-z
Kyung-Bok Son

Background: Introducing more generics has been a successful strategy for lowering pharmaceutical prices and expenditure. However, the effect of the strategy depends on the pricing schemes for generics. We aimed to update the South Korean generic markets in terms of effective competition, and to examine the effects of number of manufacturers and price variance on pharmaceutical expenditure.

Methods: We constructed balanced panel data provided by the Health Insurance Review and Assessment Service covering 726 reimbursed substances from 2019 to 2023. We developed original indicators to analyze the generic markets: the maximum-minimum price variance (MMPV) and the maximum-weighted price variance (MWPV). Panel regression with fixed and time-fixed effects was used.

Results: Over the study period, the number of manufacturers increased from 17.81 in 2019 to 20.98 in 2020 and then decreased to 18.70 in 2023. The MMPV increased from 204.70 in 2019 to 230.07 in 2022 and then decreased slightly to 225.34 in 2023. The MWPV increased from 59.70 in 2019 to 72.58 in 2023. Two types of segmented markets were noteworthy: low use of low-cost generics with sufficient manufacturers and high use of low-cost generics with insufficient manufacturers. In the fixed and time-fixed effects panel analyses, the MWPV presented a negative association with the number of manufacturers and a positive association with the MMPV.

Conclusions: A newly introduced tiered pricing scheme, designed to differentiate generic prices, was associated with a decrease in the number of manufacturers and an increase in price dispersion. The pricing schemes for generics should be designed with price variance in mind and limit the number of too many generics in South Korea.

背景:引入更多非专利药是降低药品价格和开支的成功策略。然而,该战略的效果取决于仿制药的定价方案。我们旨在更新韩国仿制药市场的有效竞争情况,并研究生产商数量和价格差异对药品支出的影响:我们构建了由健康保险审查和评估服务机构提供的平衡面板数据,涵盖 2019 年至 2023 年的 726 种报销物质。我们开发了分析仿制药市场的原创指标:最大最小价格差异(MMPV)和最大加权价格差异(MWPV)。我们使用了具有固定效应和时间固定效应的面板回归:在研究期间,生产商数量从 2019 年的 17.81 家增至 2020 年的 20.98 家,然后降至 2023 年的 18.70 家。市场销售量从 2019 年的 204.70 增加到 2022 年的 230.07,然后略微下降到 2023 年的 225.34。总市盈率从 2019 年的 59.70 增至 2023 年的 72.58。值得注意的是两类细分市场:低成本仿制药使用率低且生产商充足,以及低成本仿制药使用率高且生产商不足。在固定效应和时间固定效应面板分析中,MWPV 与生产商数量呈负相关,而与 MMPV 呈正相关:结论:为区分仿制药价格而新推出的分级定价方案与生产商数量减少和价格分散度增加有关。仿制药定价方案的设计应考虑到价格差异,并限制韩国仿制药数量过多。
{"title":"Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea.","authors":"Kyung-Bok Son","doi":"10.1186/s13561-024-00545-z","DOIUrl":"10.1186/s13561-024-00545-z","url":null,"abstract":"<p><strong>Background: </strong>Introducing more generics has been a successful strategy for lowering pharmaceutical prices and expenditure. However, the effect of the strategy depends on the pricing schemes for generics. We aimed to update the South Korean generic markets in terms of effective competition, and to examine the effects of number of manufacturers and price variance on pharmaceutical expenditure.</p><p><strong>Methods: </strong>We constructed balanced panel data provided by the Health Insurance Review and Assessment Service covering 726 reimbursed substances from 2019 to 2023. We developed original indicators to analyze the generic markets: the maximum-minimum price variance (MMPV) and the maximum-weighted price variance (MWPV). Panel regression with fixed and time-fixed effects was used.</p><p><strong>Results: </strong>Over the study period, the number of manufacturers increased from 17.81 in 2019 to 20.98 in 2020 and then decreased to 18.70 in 2023. The MMPV increased from 204.70 in 2019 to 230.07 in 2022 and then decreased slightly to 225.34 in 2023. The MWPV increased from 59.70 in 2019 to 72.58 in 2023. Two types of segmented markets were noteworthy: low use of low-cost generics with sufficient manufacturers and high use of low-cost generics with insufficient manufacturers. In the fixed and time-fixed effects panel analyses, the MWPV presented a negative association with the number of manufacturers and a positive association with the MMPV.</p><p><strong>Conclusions: </strong>A newly introduced tiered pricing scheme, designed to differentiate generic prices, was associated with a decrease in the number of manufacturers and an increase in price dispersion. The pricing schemes for generics should be designed with price variance in mind and limit the number of too many generics in South Korea.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"64"},"PeriodicalIF":2.7,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historical origins of corruption in the Romanian public health system - path dependency and contagion effect. 罗马尼亚公共卫生系统腐败的历史渊源--路径依赖和传染效应。
IF 2.7 3区 经济学 Q1 ECONOMICS Pub Date : 2024-08-07 DOI: 10.1186/s13561-024-00543-1
Aurelian-Petruş Plopeanu

Background: In this paper, we estimate the long-lasting influence of the former Habsburg Empire's border on the territory of Romania, specifically on the prevalence of corrupt behaviour and practices in health services.

Methods: Employing microdata from the 2016 Life in Transition Survey and applying ordered probit regression, we explore the hypothesis that the geographical proximity of respondents' residences to the former imperial border-restricting the analysis within a bandwidth of 50 km, 75 km or even 100 km on either side - significantly influences current individual tendencies towards corrupt behaviour.

Results: The results indicate that individuals in Transylvania living in the immediate vicinity of the former border of the Habsburg Empire (no more than 75 km away) show a higher propensity towards corrupt behaviours, similar to those from Moldova and Wallachia who reside in the same bandwidth but to the east of the former historical border. Interestingly, on one hand, after a series of tests with various relevant factors, the contagion effect is observed from right to left, meaning from those in Moldova and Wallachia towards those in Transylvania, and not the other way around as might be expected based on other previous studies. On the other hand, individuals living more than 75 kms west of the former historical border show clear reluctance to engage in informal payments and gift-giving when interacting with the public health system as patients.

Conclusion: By rigorously controlling for various variables that comprehensively show different legacies of the communist regime, our results confirm the persistence of these influences across different bandwidths, thereby corroborating the hypothesis of path dependence influenced by the former Habsburg Empire.

背景:在本文中,我们估算了前哈布斯堡帝国边界对罗马尼亚领土的长期影响,特别是对医疗服务中腐败行为和做法的普遍性的影响:我们利用 2016 年 "转型期生活调查 "中的微观数据,运用有序 probit 回归法,探讨了受访者居住地与前帝国边界的地理距离--将分析限制在两侧 50 公里、75 公里甚至 100 公里的带宽内--会显著影响当前个人腐败行为倾向的假设:结果表明,居住在哈布斯堡帝国前边界附近(不超过 75 公里)的特兰西瓦尼亚人表现出更高的腐败行为倾向,这与居住在同一带宽内但位于前历史边界以东的摩尔多瓦人和瓦拉几亚人相似。有趣的是,一方面,在对各种相关因素进行一系列测试后,发现传染效应是从右向左的,即从摩尔多瓦和瓦拉几亚的人向特兰西瓦尼亚的人传染,而不是像之前其他研究预期的那样。另一方面,居住在前历史边界以西 75 公里以上的居民在以患者身份与公共医疗系统互动时,明显不愿意进行非正式支付和赠送礼品:通过严格控制各种变量(这些变量全面显示了共产主义政权的不同遗产),我们的结果证实了这些影响在不同带宽上的持续性,从而证实了受前哈布斯堡帝国影响的路径依赖假设。
{"title":"Historical origins of corruption in the Romanian public health system - path dependency and contagion effect.","authors":"Aurelian-Petruş Plopeanu","doi":"10.1186/s13561-024-00543-1","DOIUrl":"10.1186/s13561-024-00543-1","url":null,"abstract":"<p><strong>Background: </strong>In this paper, we estimate the long-lasting influence of the former Habsburg Empire's border on the territory of Romania, specifically on the prevalence of corrupt behaviour and practices in health services.</p><p><strong>Methods: </strong>Employing microdata from the 2016 Life in Transition Survey and applying ordered probit regression, we explore the hypothesis that the geographical proximity of respondents' residences to the former imperial border-restricting the analysis within a bandwidth of 50 km, 75 km or even 100 km on either side - significantly influences current individual tendencies towards corrupt behaviour.</p><p><strong>Results: </strong>The results indicate that individuals in Transylvania living in the immediate vicinity of the former border of the Habsburg Empire (no more than 75 km away) show a higher propensity towards corrupt behaviours, similar to those from Moldova and Wallachia who reside in the same bandwidth but to the east of the former historical border. Interestingly, on one hand, after a series of tests with various relevant factors, the contagion effect is observed from right to left, meaning from those in Moldova and Wallachia towards those in Transylvania, and not the other way around as might be expected based on other previous studies. On the other hand, individuals living more than 75 kms west of the former historical border show clear reluctance to engage in informal payments and gift-giving when interacting with the public health system as patients.</p><p><strong>Conclusion: </strong>By rigorously controlling for various variables that comprehensively show different legacies of the communist regime, our results confirm the persistence of these influences across different bandwidths, thereby corroborating the hypothesis of path dependence influenced by the former Habsburg Empire.</p>","PeriodicalId":46936,"journal":{"name":"Health Economics Review","volume":"14 1","pages":"63"},"PeriodicalIF":2.7,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11308148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"经济学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Health Economics Review
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1